Terms ending in 2037
Every in-force patent on Bold Limited's record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,633,380 | Use of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE(III)] for the Treatment of Cancer In force · Low confidence | Bold Therapeutics, Inc. | In force | Low confidence |
1 of 1 patent shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.